Early Results from Clinical Trials of New Tuberculosis Vaccines

Early Results from Clinical Trials of New Tuberculosis Vaccines 11/2/2006
Paris, France

Subscribe to World Conference on Lung Health 2006 Podcasts

Full version:

Video

Podcast

Transcript

Speakers for this session:

Chairpersons

Larry Geiter, Ph.D., M.P.H.
USA
Consultant
Sequella Global Tuberculosis Foundation
Jerald Sadoff, M.D.
USA
President and Chief Executive Officer
Aeras Global TB Vaccine Foundation

Video

Results From a Randomised Controlled Trial Comparing Intradermal and Percutaneous Administration

Anthony Hawkridge
South Africa
Clinical Director
Institute of Infectious Disease and Molecular Medicine
University of Cape Town

Video |

Slides |

GlobalHealthReporting Country Profile: South Africa

BCG and Ad35 Vector

Jerald Sadoff, M.D.
USA
President and Chief Executive Officer
Aeras Global TB Vaccine Foundation

Video |

Slides |

GlobalHealthFacts Country Profile: United States of America

TB Submit Vaccines Based on Fusion Proteins

Peter Andersen ** Unavailable for webcasting.

Denmark
Vice President
Vaccine Research and Development
Statens Serum Institut

GlobalHealthFacts Country Profile: Denmark

BCG Escaping the Endosome

Stefan Kauffman, Ph.D.
Germany
Director
Department of Immunology
Max Planck Institute for Infection Biology

Video |

Slides |

GlobalHealthFacts Country Profile: Germany

MVA-85a

Helen McShane, M.D.
United Kingdom
Department of Public Health, University of Oxford

Video |

Slides |

GlobalHealthFacts Country Profile: United Kingdom

Cost-Effectiveness and Potential Impact of New TB Vaccines

Richard Menzies, M.D.
Canada
Director
Respiratory Epidemiology Unit
McGill University

Video |

Slides |

GlobalHealthFacts Country Profile: Canada

EMAIL ALERTS
Sign up for email alerts and stay informed about upcoming HealthCasts, and the latest health policy issues, news and events.

FAQs

More...

CONTACT US
Contact us by email with any comments, problems, suggestions.
Call the kaisernetwork.org Help Desk at 202-347-5270.

...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ......